In Portugal, the authorities are planning what to do regarding the introduction of biosimilars. Biologic medicines are fully reimbursed by the NHS (either patients do the treatment in a hospital setting, or they can have the prescription to collect the product in hospital pharmacies, according to which biologic treatment they are prescribed).
Patients and patients organisations are concerned with the possibility of interchangeability if the authorities decide to make biosimilars available by purchase only.
- Could you let us know how is this being dealt with in your countries?
- Are you aware of any evidence regarding interchangeability?